Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/28 09:32:56 pm
115.3895 USD   -0.27%
06:41p JOHNSON & JOHNS : Does baby powder cause cancer? Another jury says y..
12:21p JOHNSON & JOHNS : Woman wins £58m after claiming Johnson's baby powd..
09:21a JOHNSON & JOHNS : St. Louis jury awards $70 million to woman claimin..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 07:41pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
06:41p JOHNSON & JOHNSON : Does baby powder cause cancer? Another jury says yes.
04:22p JOHNSON & JOHNSON : Health Workers, Others Exposed to Cervical Cancer Prevention
12:21p JOHNSON & JOHNSON : Woman wins £58m after claiming Johnson's baby powder gave he..
09:21a JOHNSON & JOHNSON : St. Louis jury awards $70 million to woman claiming baby pow..
06:11a JOHNSON & JOHNSON : Jury awards more than $70M to woman in baby powder lawsuit
10/27 Johnson & Johnson Reports 2016 Third-Quarter Results
10/27 Verb Surgical Inc. Honored by Goldman Sachs for Entrepreneurship - Scott Huen..
10/27 JOHNSON & JOHNSON : Jules Musing, Former Senior Executive at Johnson & Johnson, ..
10/27 JOHNSON & JOHNSON : Pinnacle Advisory Group buys $1,202,448 stake in Johnson & J..
10/27 JOHNSON & JOHNSON (NYSE : JNJ) Faces Competition From Mylan Concerta Knockoff
More news
Sector news : Pharmaceuticals - NEC
07:06pDJEU Opens In-Depth Probe Into ChemChina's Bid for Syngenta
06:34p FTSE edges higher as IAG boosts travel stocks
03:56pDJABBVIE : Sales of AbbVie's Humira Miss Expectations
03:47pDJABBVIE : Revenue and Profit Rise, but Humira Misses Expectations
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:00a GLAXOSMITHKLINE : Has Q3 2016 Seen The Positive Momentum Continue Building?
10/27 Should You Buy Pfizer Now?
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,71%
P/E ratio 2016 19,58
P/E ratio 2017 17,26
EV / Sales 2016 4,12x
EV / Sales 2017 3,84x
Capitalization 316 541 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON12.64%316 541
ROCHE HOLDING LTD.-18.05%200 403
PFIZER INC.0.62%197 012
NOVARTIS AG-17.97%188 860
MERCK & CO., INC.16.04%169 480
SANOFI-12.39%96 780
More Results